Boothbay Fund Management LLC Cuts Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Boothbay Fund Management LLC lessened its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 26.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,746 shares of the company's stock after selling 14,633 shares during the period. Boothbay Fund Management LLC owned 0.14% of LENZ Therapeutics worth $1,147,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of LENZ Therapeutics during the third quarter worth approximately $286,000. Barclays PLC lifted its stake in shares of LENZ Therapeutics by 273.1% in the 3rd quarter. Barclays PLC now owns 16,463 shares of the company's stock worth $391,000 after acquiring an additional 12,051 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in shares of LENZ Therapeutics in the fourth quarter valued at about $1,270,000. SG Americas Securities LLC increased its stake in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after acquiring an additional 935 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in LENZ Therapeutics during the fourth quarter worth about $168,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on LENZ shares. Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Wednesday, April 16th. TD Cowen assumed coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price for the company. Finally, Citigroup upped their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $46.60.

LENZ Therapeutics Stock Performance

LENZ stock traded up $0.64 on Friday, reaching $29.52. The company had a trading volume of 267,059 shares, compared to its average volume of 185,099. The company's fifty day moving average is $24.07 and its 200 day moving average is $27.29. The company has a market cap of $813.07 million, a P/E ratio of -6.19 and a beta of 0.43. LENZ Therapeutics, Inc. has a 1 year low of $14.42 and a 1 year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, sell-side analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.